207 related articles for article (PubMed ID: 34478126)
1. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
Cockerham KP; Padnick-Silver L; Stuertz N; Francis-Sedlak M; Holt RJ
Ophthalmol Ther; 2021 Dec; 10(4):975-987. PubMed ID: 34478126
[TBL] [Abstract][Full Text] [Related]
2. Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States.
Wang Y; Sharma A; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Massry G; Douglas RS
Ophthalmol Ther; 2021 Mar; 10(1):75-87. PubMed ID: 33196932
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States.
Wang Y; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Douglas RS
Endocr Pract; 2022 Sep; 28(9):842-846. PubMed ID: 35714862
[TBL] [Abstract][Full Text] [Related]
4. How patients experience thyroid eye disease.
Smith TJ; Hegedüs L; Lesser I; Perros P; Dorris K; Kinrade M; Troy-Ott P; Wuerth L; Nori M
Front Endocrinol (Lausanne); 2023; 14():1283374. PubMed ID: 38027128
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients.
Son BJ; Lee SY; Yoon JS
Can J Ophthalmol; 2014 Apr; 49(2):167-73. PubMed ID: 24767223
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
Thyroid; 2024 Jun; ():. PubMed ID: 38824618
[No Abstract] [Full Text] [Related]
8. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
9. Teprotumumab for the treatment of thyroid eye disease.
Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
[TBL] [Abstract][Full Text] [Related]
10. Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values.
Smith TJ; Cockerham K; Barretto N; Hirst A; Oliver L; Enstone A; Brandolini G; Taylor SD; Holt RJ
Endocr Pract; 2024 May; 30(5):470-475. PubMed ID: 38341128
[TBL] [Abstract][Full Text] [Related]
11. Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States.
Smith TJ; Cockerham K; Lelli G; Choudhary C; Taylor S; Barretto N; Enstone A; Oliver L; Lynch J; Holt RJ
JAMA Ophthalmol; 2023 Feb; 141(2):159-166. PubMed ID: 36580313
[TBL] [Abstract][Full Text] [Related]
12. The Psychosocial and Clinical Outcomes of Orbital Decompression Surgery for Thyroid Eye Disease and Predictors of Change in Quality of Life.
Wickwar S; McBain H; Ezra DG; Hirani SP; Rose GE; Newman SP
Ophthalmology; 2015 Dec; 122(12):2568-76.e1. PubMed ID: 26421706
[TBL] [Abstract][Full Text] [Related]
13. Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm.
Wang Y; Patel A; Douglas RS
Ther Clin Risk Manag; 2019; 15():1305-1318. PubMed ID: 31814726
[TBL] [Abstract][Full Text] [Related]
14. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease.
Fayers T; Dolman PJ
Br J Ophthalmol; 2011 Dec; 95(12):1670-4. PubMed ID: 21951566
[TBL] [Abstract][Full Text] [Related]
15. Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Ben Simon G
Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2009-2015. PubMed ID: 33528651
[TBL] [Abstract][Full Text] [Related]
16. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Diabetic and Nondiabetic Patients With Thyroid Eye Disease in the United States: A Claims-Based Analysis.
Patel VK; Padnick-Silver L; D'Souza S; Bhattacharya RK; Francis-Sedlak M; Holt RJ
Endocr Pract; 2022 Feb; 28(2):159-164. PubMed ID: 34781042
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease.
Fayers T; Fayers PM; Dolman PJ
Orbit; 2016 Dec; 35(6):328-334. PubMed ID: 27599688
[TBL] [Abstract][Full Text] [Related]
20. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
